|March 12, 2014|
|10:44 EDT||ZQK, JOSB, PANW, NLNK, BIG||Options with decreasing implied volatility: NLNK JOSB BIG PANW ZQK|
News For NLNK;JOSB;BIG;PANW;ZQK From The Last 14 Days
|October 6, 2015|
|13:26 EDT||PANW||Radware plunges after negative Q3 pre-announcement|
Shares of cybersecurity and application delivery solutions company Radware (RDWR) are plunging after the company announced preliminary third quarter results that were below previous guidance. WHAT'S NEW: On Monday evening, Radware announced preliminary adjusted earnings per share of 10c, well below its guidance of 23c-24c and analysts' consensus estimates of 24c. Radware also reported preliminary Q3 revenue of $48M, below its prior view of $57M-$59M and analysts' consensus estimates of $57.95M. WHAT'S NOTABLE. On the company's conference call discussing the preliminary results, the company noted that the mix between supporting and subscription sales to product sales was weighted much heavier than usual towards subscription and service contracts. As these sales are recognized over the life of the contract, the company recognized revenue of only $48M for the quarter. The weakness in the quarter came primarily from the U.S. carrier and service provider markets, said Roy Zisapel, the company's chief executive officer. The company noted that several large deals that were expected to be booked at the end of the quarter did not materialize. The company subsequently booked one of those deals and expects to book many of the remaining deals. On the call, the company said it continues to face weakness in China and FX headwinds in Brazil and Russia that impacted revenue. ANALYST TAKE: In a note to investors this morning, Oppenheimer analyst Ittai Kidron downgraded shares of Radware to Perform from Outperform, removing its $23 price target and cutting estimates for 2015 and 2016. The analyst, who put the note out before the conference call, said it suspects "the miss is tied to execution issues related to the inherently lumpy service provider business." Wells Fargo also downgraded Radware to Market Perform from Outperform. PRICE ACTION: Shares of Radware are sliding 21.59% to $13.58 in afternoon trading. OTHERS TO WATCH: Shares of other companies involved in cybersecurity are underperforming the broader market with FireEye (FEYE) down 2.95%, Palo Alto Networks (PANW) sliding 2.39%, Check Point (CHKP) lower by 3.48% and Imperva (IMPV) down 1.85%.
|October 5, 2015|
|06:11 EDT||PANW||Apple iOS users in China, Taiwan targeted by ad-focused malware|
Subscribe for More Information
|October 2, 2015|
|15:14 EDT||PANW||As many as 4.6M Scottrade users' data exposed in breach, KrebsonSecurity says|
Subscribe for More Information
|October 1, 2015|
|07:23 EDT||NLNK||NewLink Genetics awarded $18M contract option from BARDA |
NewLink Genetics Corporation (NLNK) announced today that the Biomedical Advanced Research and Development Authority, or BARDA, of the United States Department of Health and Human Services, or HHS, has exercised an $18M option on NewLink Genetics' existing contract to support the scale-up of the manufacturing process relating to its investigational rVSV-ZEBOV GP vaccine candidate. BARDA made an initial $30M contract award to NewLink in late 2014 and is now providing additional funding to continue development of the Ebola vaccine candidate. Merck (MRK) has the license for research, development, manufacturing and commercialization of the rVSV-ZEBOV GP vaccine.
|07:23 EDT||NLNK||NewLink Genetics awarded $18M contract option from BARDA|
Subscribe for More Information
|September 30, 2015|
|10:33 EDT||PANW||Battleground: Analysts agree Barracuda shares 'cheap,' diverge on ratings|
The shares of Barracuda Networks (CUDA) are falling after the company reported lower than expected revenue and provided weaker than expected guidance. Research firms Piper Jaffray and JPMorgan both said that the shares are cheap in the wake of their huge decline today, though Piper downgraded the shares and JPMorgan kept an Overweight rating on the stock. Barracuda provides IT security and storage solutions, primarily for small and medium businesses. WHAT'S NEW: Barracuda last night reported second quarter earnings per share of 10c, versus analysts' consensus estimate of 9c. The company's revenue, however, came in at $78.4M, below the consensus outlook of $78.7M. Moreover, the company lowered its fiscal 2016 EPS guidance to 34c-36c from 36c-41c. Analysts' consensus estimate was 39c. Barrcuda cut its full-year revenue guidance to $320M-$323M, from $325M-$330M. Analysts' consensus estimate was $325M. The company said that its Q2 results were negatively impacted by longer sales cycles in its Europe, Middle East, and Africa region and it warned that it "saw some evidence" of slowing growth in the storage market. It also stated that its gross billings came in below its expectations. ANALYST REACTION: Piper Jaffray analyst Andrew Nowinski responded to Barracuda's results by downgrading the stock to Neutral from Overweight. Although Barracuda blamed its lower than expected billings guidance on weakness in its storage business, its security billings increased only by high single digit percentage levels, the analyst stated. The shares are "cheap," but the valuation is not compelling enough to recommend the stock, contends Nowinski, who cut his price target for shares to $20 from $40. Barracuda was also downgraded at Macquarie and at Stephens this morning.Conversely, JPMorgan analyst Sterling Auty called Barracuda shares "too cheap to ignore." The company lowered its billings guidance partly due to worries about slowing storage market growth, as indicated by an industry report released last quarter, said Auty. However, the growth of Barracuda's storage business actually accelerated last quarter, reaching about 25%, the analyst stated. He believes that Barracuda's new guidance reflects the company's efforts to be "prudent." Auty cut his price target on the name to $30 from $42 but kept an Overweight rating on the shares. OTHERS TO WATCH: Other publicly traded companies in the IT security space include Check Point (CHKP), F5 Networks (FFIV), FireEye (FEYE), Fortinet (FTNT), Imperva (IMPV), Palo Alto (PANW), Proofpoint (PFPT), Qualys (QLYS) and Symantec (SYMC). PRICE ACTION: In early trading, Barracuda tumbled 33% to $15.90.
|08:02 EDT||PANW||Trustwave and Palo Alto announce strategic alliance|
Trustwave and Palo Alto announced a strategic alliance designed to bring next-generation managed security services to global, multi-national businesses and government agencies. Under the terms of the agreement, Trustwave has become a global member of the Palo Alto Networks NextWave partner program to provide managed security services for the Palo Alto Networks security platform.
|September 29, 2015|
|08:39 EDT||NLNK||Oracle Health Sciences adds 93 biopharma customers|
Oracle (ORCL) Health Sciences announced that 93 emerging biopharma organizations worldwide have become new customers in the past year, adopting Oracle Health Sciences solutions to succeed in this rapidly evolving market and deliver drugs to patients faster. Organizations, including Accera and NewLink (NLNK), selected Oracle Health Sciences solutions to manage their end-to-end clinical trial processes, boost clinical development productivity, facilitate compliance, and build scalable, affordable platforms for growth.
|September 28, 2015|
|16:19 EDT||NLNK||On The Fly: Top stock stories for Monday|
Stocks on Wall Street were sharply lower as investors continue to worry about the health of China's economy and continue to flee the biotech sector. The iShares NASDAQ Biotechnology Index (IBB) was down 6.33% today and is down about 18.5% since September 21, when Democratic presidential candidate Hillary Clinton pledged to take action against the high prices of specialty drugs. Adding to the tentative mood among investors was noted investor Carl Icahn's preview for a presentation that will be made available on his site tomorrow, entitled "Danger Ahead." The preview includes several cautious comments that the billionaire has publicly made recently regarding his concerns about the high-yield bond market and the stock market. ECONOMIC EVENTS: In the U.S., personal income grew 0.3% in August, versus expectations for it to rise 0.4%. Personal spending rose 0.4% last month, versus expectations for growth of 0.3%. The pending home sales index fell 1.4% in August, missing expectations for it to have risen 0.4%. The Dallas Fed manufacturing outlook survey for September had a reading of -9.5, versus expectations for a reading of -10.0. In China, industrial profits plunged 8.8% in August, adding to the recent string of weak data from the Asian giant. COMPANY NEWS: Apple (AAPL) reported that it set a record by selling more than 13M new iPhone 6s and iPhone 6s Plus models in the first three days after launch of the devices. However, shares of the tech giant slid about 2% to $112.44 following the announcement... Alcoa (AA) shares advanced 52c, or 5.73%, to $9.59 after the company announced that its board has approved a plan to separate into two independent, publicly-traded companies - an Upstream company that will operate under the Alcoa name and a new "Value-Add company" that will provide high-performance, multi-material products whose name will be announced at a later date... Biotech stocks continued recent declines, with Valeant (VRX) dropping 16.6% after a group of Democratic congressmen urged additional scrutiny of the company's "price hike" business model, while Epizyme (EPZM) and NewLink (NLNK) fell a respective 27% and 21% after presenting data at the 2015 European Cancer Congress... Shares of both Energy Transfer Equity (ETE) and Williams (WMB) fell after they announced a combination deal valued at approximately $37.7B, including the assumption of debt and other liabilities. Under the terms of their deal, an affiliate of ETE will acquire Williams at an implied current price of $43.50 per Williams share, the companies said. In late June, Energy Transfer Equity made a proposal to merge with Williams in an all-equity transaction valued at that time at $53.1B, including the assumption of debt and other liabilities. Under that prior merger proposal, ETE would have acquired all of the outstanding common stock of Williams at an implied price of $64 per Williams share, which represented a 32.4% premium to Williams' common share closing price as of June 19. Energy Transfer Equity shares closed down $2.95, or 12.69%, to $20.29 after announcing today's revised deal, while Williams dropped $5.03, or 12.09%, to close at $36.57. MAJOR MOVERS: Among the notable gainers was Republic Airways (RJET), which surged $2.38, or 81.8%, to $5.29 after announcing that the company and Teamsters Local 357 have reached a consensual tentative agreement on the terms of a new three-year contract for the 2,100 Republic pilots represented by the International Brotherhood of Teamsters. Also higher was Media General (MEG), which gained $2.49, or 22.3%, to $13.64 after Nexstar (NXST) proposed a cash-and-stock deal to acquire the company for $14.50 per share, which Media General said it would "carefully review." Additionally, Sanchez Energy (SN) rose 4.5% to $5.57 after agreeing to sell certain Eagle Ford Shale midstream assets to Sanchez Production Partners (SPP) for $345M. Among the noteworthy losers was Huntsman (HUN), which plunged $3.99, or 28.7%, to $9.92 after warning that headwinds would impact its third quarter earnings. Also lower were shares of Depomed (DEPO) and Horizon Pharma (HZNP), falling a respective 22% and 21%, after Depomed continued its criticism of Horizon's hostile takeover bid for the company. INDEXES: The Dow fell 312.78, or 1.92%, to 16,001.89, the Nasdaq lost 142.53, or 3.04%, to 4,543.97, and the S&P 500 dropped 49.57, or 2.57%, to 1,881.77.
|September 27, 2015|
|17:02 EDT||NLNK||NewLink Genetics reports early Phase 1a data on GDC-0919|
Subscribe for More Information
|15:55 EDT||NLNK||NewLink Genetics presents early Phase 1b data on indoximod|
NewLink Genetics presented early-stage clinical data from a Phase 1b study of indoximod, its wholly owned indoleamine 2,3 dioxygenase pathway inhibitor, in combination with ipilimumab for the treatment of patients with unresectable stage 3 or 4 melanoma. The data reported are from a safety study of nine patients to determine the safety of indoximod and to establish the dose for a Phase 2 study in combination with ipilimumab. "Combination therapy with indoximod and ipilimumab showed encouraging clinical activity in some patients," said the company. Of the seven patients evaluable for a response, one patient had a complete response and one patient had a partial response by RECIST criteria. Five patients in the study had progressive disease, and two patients are still awaiting follow up. The combination was well-tolerated and did not demonstrate any regimen-limiting immune-based toxicities, abnormalities in liver function tests or other toxicities that have been reported with this class of drugs. The Phase 2 study, currently enrolling 38 patients, will utilize a revised study design with standard of care immune checkpoint inhibition -- consisting of four cycles of concomitant ipilimumab, repeat cycles of nivolumab or repeat cycles of pembrolizumab -- being given in combination with indoximod. The Phase 2 dose for indoximod has been established at 1,200mg twice daily.
|14:04 EDT||PANW||Cybersecurity firms look prime for takeover, Barron's says|
Cybersecurity companies like Palo Alto Networks (PANW), Fortinet (FTNT), and FireEye (FEYE) are becoming increasingly-attractive takeover targets for a Cisco (CSCO) or IBM (IBM), and any future dip in their stocks could represent a buying opportunity, Barron's contends in its 'Technology Trader' column. Reference Link
|September 25, 2015|
|10:00 EDT||BIG||On The Fly: Analyst Initiation Summary|
Today's noteworthy initiations include: AGCO (AGCO) initiated with an Equal Weight at Barclays... ARM Holdings (ARMH) initiated with a Buy at Stifel... Actuant (ATU) initiated with an Equal Weight at Barclays... Allison Transmission (ALSN) initiated with an Overweight at Barclays... Atara Biotherapeutics (ATRA) initiated with an Outperform at JMP Securities... Big Lots (BIG) initiated with a Buy at Citi... CNH Industrial (CNHI) initiated with an Underweight at Barclays... CareDx (CDNA) initiated with a Buy at Craig-Hallum... Caterpillar (CAT) initiated with an Equal Weight at Barclays... Cummins (CMI) initiated with an Underweight at Barclays... Deere (DE) initiated with an Underweight at Barclays... Genesis Energy (GEL) initiated with a Buy at Wunderlich... Joy Global (JOY) initiated with an Equal Weight at Barclays... Lincoln Electric (LECO) initiated with a Neutral at Baird... Manitowoc (MTW) initiated with an Equal Weight at Barclays... Navistar (NAV) initiated with an Underweight at Barclays... Nevro (NVRO) initiated with an Outperform at BMO Capital... PACCAR (PCAR) initiated with an Underweight at Barclays... PBF Energy (PBF) initiated with a Neutral at Goldman... PayPal (PYPL) initiated with a Buy at Canaccord... Quanex (NX) initiated with a Buy at Sidoti... Team Health (TMH) initiated with a Buy at Jefferies... Terex (TEX) initiated with an Equal Weight at Barclays... United Rentals (URI) initiated with an Overweight at Barclays... WABCO (WBC) initiated with an Equal Weight at Barclays.
|09:11 EDT||BIG||Big Lots initiated with a Buy at Citi|
|September 24, 2015|
|16:03 EDT||NLNK||NewLink Genetics awarded $8.1M from DTRA to advance Ebola vaccine |
NewLink Genetics (NLNK) announced that the Defense Threat Reduction Agency of the Department of Defense has awarded a subsidiary of NewLink Genetics an $8.1M base contract with future options totaling $5.2M to support various development activities of the investigational rVSV-ZEBOV Ebola) vaccine candidate. NewLink has exclusively licensed research, development and manufacturing of the rVSV-ZEBOV vaccine to Merck (MRK). In late 2014, Merck, known as MSD outside the United States and Canada, licensed the vaccine from NewLink Genetics to apply Merck's vaccine expertise to help accelerate the development of this vaccine candidate. Clinical studies of the rVSV-ZEBOV are ongoing.
|September 23, 2015|
|20:08 EDT||PANW||Chinese president visits U.S. amid cybersecurity, copyright worries|
As part of his first official U.S. visit, Chinese president Xi Jinping held a meeting with American business leaders on Wednesday to address concerns of copyright infringement and cybersecurity, among numerous topics. In attendance were corporate giants from both nations, including Microsoft (MSFT), Apple (AAPL), Amazon (AMZN), Cisco (CSCO), Alibaba (BABA), Tencent (TCEHY), and Baidu (BIDU), according to media reports. COPYRIGHT CONCERNS: Responding to oft-cited concerns of copyright infringement by Chinese companies, Xi said China will "stand firm to protect" the intellectual property rights of American companies, according to Wall Street Journal coverage of the event. Note that in late 2014, China began establishing specialized courts to deliberate on intellectual property rights cases, and Xi commented Wednesday that "the newly established IPR courts are working smoothly. This means there will be much stronger IPR protection which will serve the interests of foreign businesses as well as Chinese companies." Chinese consumer electronics company Xiaomi is perhaps the most talked-about firm when it comes to the matter, with media outlets frequently criticizing its alleged "copying" of Apple design sensibilities. In mid-July, Xiaomi VP of global operations Hugo Barra told Bloomberg that the company is preparing to enter U.S. markets, though he cautioned that the launch could be "much more" than a year away as it seeks to build up its patent portfolio. CYBERSECURITY TENSIONS: Wednesday's meeting comes in the wake of numerous high-profile "hack attacks," with Sony (SNE), American Airlines (AAL), Anthem (ANTM), United Airlines (UAL), and Target (TGT) all reporting digital security breaches in recent years. Xi has consistently denied the involvement of state-backed hackers, but tensions have nevertheless arisen as cybersecurity firms such as FireEye (FEYE) and Palo Alto Networks (PANW) backtrace connections to the country. Cybersecurity intrusions originating from China have recently slowed ahead of Xi's visit, according to Reuters, with Kevin Mandia of security firm Mandiant telling the publication, "In my gut, I feel like the Chinese and the U.S. over the next couple of years are going to figure this out."
|12:36 EDT||PANW||Government cyber attack affects larger number of fingerprint data |
Subscribe for More Information
|12:16 EDT||PANW||Piper says reseller event positive for Palo Alto, Imperva, CyberArk|
Piper Jaffray analyst Andrew Nowinski says his investor briefing with a large security reseller yielded positive feedback on Palo Alto (PANW), Imperva (IMPV) and CyberArk (CYBR). The reseller's customers' top spending priority is now inside threat protection, which bodes well for Imperva and CyberArk, Nowinski tells investors in a research note. Further, their growth with Palo Alto continues to ramp and should exceed 50% in 2016, the analyst adds. Nowinski found comments around FireEye (FEYE) "slightly more cautious" with some viewing the Mandiant service organization as competitive to their professional service offerings.
|September 22, 2015|
|07:46 EDT||PANW||Palo Alto management to meet with Topeka|
Subscribe for More Information
|07:26 EDT||BIG||Big Lots management to meet with Deutsche Bank|
Subscribe for More Information